Stocks and Investing
Stocks and Investing
Tue, June 14, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Ashwani Verma Initiated (TEVA) at Hold and Held Target at $10 on, Jun 14th, 2022
Ashwani Verma of UBS, Initiated "Teva Pharmaceutical Industries Limited" (TEVA) at Hold and Held Target at $10 on, Jun 14th, 2022.
Ashwani has made no other calls on TEVA in the last 4 months.
There are 4 other peers that have a rating on TEVA. Out of the 4 peers that are also analyzing TEVA, 2 agree with Ashwani's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Jason Gerberry of "B of A Securities" Upgraded from Sell to Hold and Held Target at $9 on, Tuesday, May 17th, 2022
- Nathan Rich of "Goldman Sachs" Maintained at Hold with Decreased Target to $9 on, Thursday, May 12th, 2022
These are the ratings of the 2 analyists that currently disagree with Ashwani
- David Amsellem of "Piper Sandler" Downgraded from Hold to Sell and Decreased Target to $7 on, Wednesday, May 4th, 2022
- Balaji Prasad of "Barclays" Upgraded from Hold to Buy and Increased Target to $13 on, Tuesday, April 5th, 2022
Contributing Sources